Form 4: FMR LLC Sells Structure Therapeutics ADSs

FMR LLC, a significant shareholder and affiliate of Structure Therapeutics Inc., reported multiple sales of American Depositary Shares on December 8, 2025.

Summary

• FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), reported a series of transactions involving the sale of American Depositary Shares (ADSs).
• Each American Depositary Share represents three Ordinary Shares of Structure Therapeutics Inc.
• On December 8, 2025, FMR LLC, through its affiliated entities F-Prime Capital Partners Life Sciences Advisors Fund VI LP and F-Prime Capital Partners Life Sciences Fund VI LP, sold a total of 52,356 American Depositary Shares.
• The sales were executed at weighted average prices ranging from $61.05 to $94.61 per ADS.
• Following these reported transactions, F-Prime Capital Partners Life Sciences Advisors Fund VI LP indirectly beneficially owns 36,909 Ordinary Shares, and F-Prime Capital Partners Life Sciences Fund VI LP indirectly beneficially owns 434,298 Ordinary Shares.
• The total Ordinary Shares beneficially owned by persons and entities subject to reporting by FMR LLC amount to 6,062,232.
• Abigail P. Johnson, a Director, Chairman, and Chief Executive Officer of FMR LLC, is part of the Johnson family, who are the predominant owners of FMR LLC and may be deemed a controlling group.

Sentiment

Score: 4

Explanation: The filing reports significant insider selling by a major institutional investor. While the sales occurred at varying prices, including some higher ones, a reduction in ownership by a 10% owner can be perceived negatively by the market, suggesting a potential lack of strong conviction or a strategic exit/rebalancing. However, it's a routine disclosure for a large institutional investor and doesn't necessarily imply negative company performance.

Positives

• The sales of American Depositary Shares occurred at relatively high weighted average prices, with several transactions above $90 per ADS, indicating a favorable market for the seller at the time of the transactions.

Negatives

• Significant insider selling by a 10% owner and its affiliates could be perceived negatively by the market, potentially signaling a reduction in conviction or a strategic portfolio rebalancing.
• The transactions represent a decrease in the beneficial ownership of Structure Therapeutics Inc. by FMR LLC and its related entities.

Risks

• No specific risks related to Structure Therapeutics Inc.'s operations, financial health, or future prospects are mentioned in this transactional Form 4 filing.

Future Outlook

No forward-looking statements or guidance regarding Structure Therapeutics Inc.'s future performance or strategic direction are provided in this transactional filing.

Management Comments

• FMR LLC undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the weighted average prices of the transactions.
• The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.

Industry Context

This Form 4 filing details insider selling by a major institutional investor in a biotechnology or pharmaceutical company (Structure Therapeutics Inc., ticker GPCR). Such transactions are common for venture capital or private equity arms of large financial institutions as companies mature or as part of portfolio rebalancing strategies. The specific impact on Structure Therapeutics Inc. would depend on broader market sentiment towards the biotech sector and the company's specific pipeline developments.

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• FMR LLC, through its affiliates F-Prime Capital Partners Life Sciences Advisors Fund VI LP and F-Prime Capital Partners Life Sciences Fund VI LP, conducted sales of Structure Therapeutics Inc. ADSs. These funds are indirectly owned by various shareholders and employees of FMR LLC, including certain members of the Johnson family, who also control FMR LLC. This establishes a clear related-party relationship between the reporting person and the entities conducting the transactions.

Stakeholder Impact

• Shareholders: May view the insider selling by a significant institutional investor as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: May need to address market concerns if the selling is interpreted negatively, though it could also be seen as routine portfolio management.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this specific insider transaction report.

Next Steps

• No specific future actions, events, or milestones for Structure Therapeutics Inc. are mentioned in this transactional filing.

Key Dates

Recommendation

While significant insider selling by a 10% owner can be a negative signal, this Form 4 primarily reflects portfolio rebalancing by a large institutional investor (FMR LLC and its affiliates). The sales occurred at varying prices, some quite high, suggesting a strategic decision rather than a reaction to immediate negative company news. Without additional context on Structure Therapeutics Inc.'s operational performance or future prospects, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader market sentiment before making a definitive buy or sell decision.

Keywords

FMR LLC, Structure Therapeutics Inc., GPCR, SEC Form 4, Insider Selling, American Depositary Shares, ADS, Ordinary Shares, F-Prime Capital Partners, Beneficial Ownership